Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
Lancet
    December 2025
  1. SCHOENFELD JD, Haas-Kogan DA, O'Neill AF
    Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy.
    Lancet. 2025;404:2603-2604.
    >> Share

    October 2025
  2. WANG Z, Fan J, Zhou S, Sun Y, et al
    Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Lancet. 2025 Oct 19:S0140-6736(25)01720-9. doi: 10.1016/S0140-6736(25)01720.
    >> Share

  3. KASEB A, Pawlik TM
    Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma.
    Lancet. 2025 Oct 19:S0140-6736(25)02104-X. doi: 10.1016/S0140-6736(25)02104.
    >> Share

    August 2025
  4. LOOMBA R, Morgan E, Yousefi K, Li D, et al
    Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2025;406:821-831.
    >> Share

  5. NOUREDDIN M, Frias JP, Neff GW, Lucas KJ, et al
    Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet. 2025;406:719-730.
    >> Share

  6. KUDO M, Ren Z, Finn RS, Llovet JM, et al
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial - Authors' reply.
    Lancet. 2025;406:694.
    >> Share

  7. ONDER AH
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693.
    >> Share

  8. SHERRY AD, Dudzinski SO, Ludmir EB
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693-694.
    >> Share

    July 2025
  9. CHAN SL, Sun HC, Xu Y, Zeng H, et al
    The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
    Lancet. 2025 Jul 25:S0140-6736(25)01042-6. doi: 10.1016/S0140-6736(25)01042.
    >> Share

    May 2025
  10. VITHAYATHIL M, Sharma R
    Nivolumab plus ipilimumab in hepatocellular carcinoma.
    Lancet. 2025 May 7:S0140-6736(25)00417-9. doi: 10.1016/S0140-6736(25)00417.
    >> Share

  11. YAU T, Galle PR, Decaens T, Sangro B, et al
    Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
    Lancet. 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403.
    >> Share

    February 2025
  12. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    >> Share

    January 2025
  13. REITER FP, Geier A
    TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma.
    Lancet. 2025 Jan 8:S0140-6736(24)02680-1. doi: 10.1016/S0140-6736(24)02680.
    >> Share

  14. SANGRO B, Kudo M, Erinjeri JP, Qin S, et al
    Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551.
    >> Share

  15. KUDO M, Ren Z, Guo Y, Han G, et al
    Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02575-3. doi: 10.1016/S0140-6736(24)02575.
    >> Share

    November 2024
  16. ISRAELSEN M, Francque S, Tsochatzis EA, Krag A, et al
    Steatotic liver disease.
    Lancet. 2024;404:1761-1778.
    >> Share

    October 2024
  17. PONVILAWAN B, Roth MT
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1405.
    >> Share

  18. QIN S
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial - Author's reply.
    Lancet. 2024;404:1405-1406.
    >> Share

  19. WANG JK, Liao R
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1404-1405.
    >> Share

  20. LI H, Yan J, Han T
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1403-1404.
    >> Share

    September 2024
  21. ADAM R, Piedvache C, Chiche L, Adam JP, et al
    Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.
    Lancet. 2024;404:1107-1118.
    >> Share

  22. HEINEMANN V, Stintzing S
    Liver transplantation in metastatic colorectal cancer: a new standard of care?
    Lancet. 2024;404:1078-1079.
    >> Share

  23. TANAKA A, Ma X, Takahashi A, Vierling JM, et al
    Primary biliary cholangitis.
    Lancet. 2024;404:1053-1066.
    >> Share

    August 2024
  24. MAIWALL R, Kulkarni AV, Arab JP, Piano S, et al
    Acute liver failure.
    Lancet. 2024;404:789-802.
    >> Share

  25. CHOW PKH, Hack SP, Spahn JH, Yopp AC, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.
    Lancet. 2024;404:657-658.
    >> Share

  26. ROSE S, Ashraf MU, Premkumar M
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656-657.
    >> Share

  27. CHEN Z, Lan X, Du C, Xiao H, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656.
    >> Share

  28. DONADON M, Di Martino M, Rigamonti C
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:655-656.
    >> Share

  29. SHIN H, Lee JH
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:654-655.
    >> Share

    June 2024
  30. ENG C, Yoshino T, Ruiz-Garcia E, Mostafa N, et al
    Colorectal cancer.
    Lancet. 2024 Jun 20:S0140-6736(24)00360-X. doi: 10.1016/S0140-6736(24)00360.
    >> Share

    May 2024
  31. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    >> Share

    April 2024
  32. KARLSEN TH, Rutter H, Carrieri P, Zelber-Sagi S, et al
    The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.
    Lancet. 2024;403:1522-1524.
    >> Share

    November 2023
  33. VON KODOLITSCH Y, Kubisch C, Carrel T
    AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
    Lancet. 2023;402:1626.
    >> Share

  34. KUEPPERS F
    AATD as a genetic risk factor for aneurysmal disease.
    Lancet. 2023;402:1625-1626.
    >> Share

    October 2023
  35. VOGEL A, Meyer T, Saborowski A
    IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
    Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.
    >> Share

  36. QIN S, Chen M, Cheng AL, Kaseb AO, et al
    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
    >> Share

    September 2023
  37. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
    The price and value of therapeutic synergy in liver cancer.
    Lancet. 2023;402:1108-1110.
    >> Share

  38. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.
    >> Share

  39. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016